Summary
When considering the application of a screening test for any disease, it is extremely important to understand how the performance characteristics of a test will affect its usefulness to a patient as well as to society. This chapter defines and interprets the key operating characteristics for prostate-specific antigen (PSA), the ubiquitous marker used for prostate cancer screening. Results from the Prostate Cancer Prevention Trial, which broke previously held conceptions about how to use PSA, and potential biases that affect many current studies of the performance characteristics of PSA are reviewed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Thompson, I. M., Ankerst, D.P., Chi, C., Goodman, P.J., Tangen, C.M., Lucia, M.S., Feng, Z., Parnes, H.L., Coltman, C.A., Jr. (2006) Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98, 529–34.
Porter, M.P., Stanford, J.L., Lange, P.H. (2006) The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening Prostate 66,1044–51.
Schroeder, F.H., van der Maas, P., Beemsterboer, P., Kruger, A.B., Hoedemaeker, R., Rietbergen, J., Kranse, R. (1998) Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 90, 1817–23.
Thompson, I.M., Pauler, D.K., Goodman, P.J., Tangen, C.M., Lucia, M.S., Parnes, H.L., Minasian, L.M., Ford, L.G., Lippman, S.M., Crawford, E.D., Crowley, J.J., Coltman, C.A., Jr. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter New Engl J Med 350, 2239–46.
Delongchamps, N.B., Sing, A., Haas, G.P. (2006) The role of prevalence in the diagnosis of prostate cancer Cancer Control 13, 158–68.
Thompson, I.M., Ankerst, D.P., Chi, C, Lucia, M.S., Goodman, P.J., Crowley, J.J., Parnes, H.L., Coltman, C.A. (2005) Operating characteristics of Prostate Specific Antigen in men with an initial PSA level of 3.0 ng/mL or lower JAMA 294, 66–70.
Barlow, W.E., White, E., Ballard-Barbash, R., Vacek, P.M., Titus-Ernstoff, L., Carney, P.A., Tice, J.A., Buist, D.S., Geller, B.M., Rosenberg, R., Yankaskas, B.C., Kerlikowske, K. (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography J Natl Cancer Inst 98, 1204–14.
Thompson, I., Thrasher, J.B., Aus, G., Burnett, A.L., Canby-Hagino, E.D., Cookson, M.S., D’Amico, A.V., Dmochowski, R.R., Eton, D.T., Forman, J.D., Goldenberg, S.L., Hernandez, J., Higano, C.S., Kraus, S.R., Moul, J.W., Tangen, C.M. (2007) AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177, 2106–31.
Cook B. PSA Testing. Clinical Laboratory News. 34(6) June 2008. Found at http://www.aacc.org/ publications/cln/2008/June/Pages/series_0608.aspx. Verified 6/29/2008.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Thompson, I.M., Ankerst, D.P. (2009). The Performance Characteristics of Prostate-Specific Antigen for Prostate Cancer Screening. In: Ankerst, D.P., Tangen, C.M., Thompson, I.M. (eds) Prostate Cancer Screening. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-60327-281-0_6
Download citation
DOI: https://doi.org/10.1007/978-1-60327-281-0_6
Publisher Name: Humana Press
Print ISBN: 978-1-60327-280-3
Online ISBN: 978-1-60327-281-0
eBook Packages: MedicineMedicine (R0)